atorvastatin has been researched along with s 1033 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egbert, M; Keserű, GM; Vajda, S; Whitty, A | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Goudarzi, F; Hashemnia, M; Mohammadalipour, A; Ravan, AP | 1 |
2 review(s) available for atorvastatin and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
2 other study(ies) available for atorvastatin and s 1033
| Article | Year |
|---|---|
Why Some Targets Benefit from beyond Rule of Five Drugs.
Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding | 2019 |
Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis.
Topics: Animals; Atorvastatin; Carbon Tetrachloride; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Hepatic Stellate Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome | 2019 |